AR087484A2 - Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica - Google Patents

Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica

Info

Publication number
AR087484A2
AR087484A2 ARP120102894A ARP120102894A AR087484A2 AR 087484 A2 AR087484 A2 AR 087484A2 AR P120102894 A ARP120102894 A AR P120102894A AR P120102894 A ARP120102894 A AR P120102894A AR 087484 A2 AR087484 A2 AR 087484A2
Authority
AR
Argentina
Prior art keywords
dihydrotestosterone
testosterone
pharmaceutical composition
group
value
Prior art date
Application number
ARP120102894A
Other languages
English (en)
Original Assignee
Cpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087484(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cpex Pharmaceuticals Inc filed Critical Cpex Pharmaceuticals Inc
Publication of AR087484A2 publication Critical patent/AR087484A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición farmacéutica que comprende: (A) de 0,01% a 15% en peso de un andrógeno seleccionado del grupo constituido por testosterona, precursores de testosterona, sales de testosterona, complejos de testosterona, análogos de testosterona, derivados de testosterona, dihidrotestosterona, precursores de dihidrotestosterona, congéneres de dihidrotestosterona, sales de dihidrotestosterona, complejos de dihidrotestosterona, análogos de dihidrotestosterona y derivados de dihidrotestosterona; (B) de 0,01% a 25% en peso de un potenciador de Hsieh, que es un compuesto de la fórmula estructural (1) en la que X e Y son oxígeno, azufre o un grupo imino de la estructura de fórmula (2) o =N-R; con la condición de que cuando Y es un grupo imino, X es un grupo imino, y cuando Y es azufre, X es azufre o un grupo imino; A es un grupo que tiene la estructura de fórmula (3) en la que X e Y son como se han definido anteriormente; m y n son números enteros que tienen un valor de 1 a 20 y la suma de m + n no es mayor de 25; p es un número entero que tiene un valor de 0 ó 1; q es un número entero que tiene un valor de 0 ó 1; r es un número entero que tiene un valor de 0 ó 1; y cada uno de R, R1, R2, R3, R4, R5 y R6 es de manera independiente hidrógeno o un grupo alquilo que tiene de 1 a 6 átomos de carbono que puede ser de cadena lineal o ramificada, con la condición de que sólo uno de R1 a R6 puede ser un grupo alquilo; con la condición de que cuando p, q y r son 0, e Y es oxígeno, entonces m + n es al menos 11; y con la condición adicional de que cuando X es un grupo imino, q es igual a 1, Y es oxígeno, y p y r son 0, entonces m + n es al menos 11; (C) de 0,1% a 10% en peso de un agente espesante; y el uso de la composición para la fabricación de un medicamento para administrar un andrógeno a un paciente.
ARP120102894A 2002-04-19 2012-08-08 Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica AR087484A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19

Publications (1)

Publication Number Publication Date
AR087484A2 true AR087484A2 (es) 2014-03-26

Family

ID=29251138

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101362A AR039644A1 (es) 2002-04-19 2003-04-21 Composicion farmaceutica que comprende un androgeno, un mejorador de hsieh y un agente espesante.
ARP120102894A AR087484A2 (es) 2002-04-19 2012-08-08 Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030101362A AR039644A1 (es) 2002-04-19 2003-04-21 Composicion farmaceutica que comprende un androgeno, un mejorador de hsieh y un agente espesante.

Country Status (30)

Country Link
US (21) US7320968B2 (es)
EP (2) EP1425019B1 (es)
JP (1) JP2005519985A (es)
KR (2) KR100977896B1 (es)
CN (2) CN1662243B (es)
AR (2) AR039644A1 (es)
AT (1) ATE371456T1 (es)
AU (1) AU2003228612B2 (es)
BR (1) BR0309390A (es)
CA (1) CA2470200C (es)
CY (1) CY1109005T1 (es)
DE (1) DE60315939T2 (es)
DK (1) DK1425019T3 (es)
EA (1) EA009839B1 (es)
EG (1) EG24882A (es)
ES (2) ES2292964T3 (es)
HK (3) HK1082682A1 (es)
IL (1) IL164547A (es)
IS (2) IS2667B (es)
LT (1) LT5235B (es)
LV (1) LV13303B (es)
MX (1) MXPA04010311A (es)
MY (1) MY139721A (es)
NO (1) NO335864B1 (es)
NZ (1) NZ535970A (es)
PL (1) PL213976B1 (es)
SA (1) SA03240158B1 (es)
TW (1) TWI362932B (es)
WO (1) WO2003088974A1 (es)
ZA (1) ZA200408422B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
MX2007002814A (es) * 2004-09-09 2007-05-16 Besins Int Lab Geles de testosterona comprendiendo propilenglicol como mejorador de penetracion.
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CN101287470B (zh) 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 改良的睾酮凝胶及使用方法
MX2010012261A (es) * 2008-05-09 2011-04-07 Tolmar Inc Proguanil para tratar enfermedades de la piel/mucosa.
CN102056593A (zh) * 2008-06-05 2011-05-11 Cpex药品公司 胰岛素鼻用制剂
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
US9642863B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
DK2714006T3 (da) * 2011-05-15 2021-03-15 Acerus Biopharma Inc Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
EP4186545A1 (en) 2012-04-06 2023-05-31 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
AU2013318229B2 (en) 2012-09-20 2017-07-06 Gkn Armstrong Wheels, Inc. Lock ring spreader
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE843140A (fr) 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US3989815A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3991203A (en) 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4424210A (en) 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4423040A (en) 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4415563A (en) 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4992422A (en) 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
RU2211047C2 (ru) 1997-01-30 2003-08-27 Новартис Аг Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
DE29704393U1 (de) 1997-03-11 1997-07-17 Aesculap Ag, 78532 Tuttlingen Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
ES2318233T3 (es) * 1997-11-10 2009-05-01 Strakan International Limited Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona.
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
FR2801507B1 (fr) * 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
BR0008058A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
EP1322336B1 (en) * 2000-08-30 2013-07-03 Unimed Pharmaceuticals, LLC Method of increasing testosterone and related steroid concentrations in women
TR200300776T2 (tr) 2000-08-30 2005-10-21 Unimed Pharmaceuticals, Inc. Erkeklerde cinsel organ sertleşmemesinin tedavi edilmesi ve libidonun arttırılması için yöntem.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
ES2283446T3 (es) 2000-12-22 2007-11-01 DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal.
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US6980852B2 (en) 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
KR20050074896A (ko) 2002-03-15 2005-07-19 유니메드 파마슈티칼스, 인크. 우울증 치료용 안드로겐 제약 조성물 및 방법
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
KR20090079266A (ko) 2009-07-21
US20050192260A1 (en) 2005-09-01
US20140343025A1 (en) 2014-11-20
US7608607B2 (en) 2009-10-27
NO335864B1 (no) 2015-03-09
ES2292964T3 (es) 2008-03-16
NZ535970A (en) 2006-12-22
US20090118252A1 (en) 2009-05-07
US8063029B2 (en) 2011-11-22
IS8870A (is) 2010-01-06
US20090124589A1 (en) 2009-05-14
US20090131387A1 (en) 2009-05-21
US20210308146A1 (en) 2021-10-07
KR20050011753A (ko) 2005-01-29
EP1425019A1 (en) 2004-06-09
CN102357098B (zh) 2014-12-17
NO20045019L (no) 2005-01-14
DE60315939T2 (de) 2008-05-21
US20210308145A1 (en) 2021-10-07
CN102357098A (zh) 2012-02-22
AU2003228612B2 (en) 2006-05-04
LV13303B (en) 2006-08-20
CA2470200C (en) 2005-07-26
HK1167332A1 (en) 2012-11-30
DK1425019T3 (da) 2008-02-04
EA009839B1 (ru) 2008-04-28
EA200401410A1 (ru) 2005-04-28
BR0309390A (pt) 2005-02-09
EP1425019B1 (en) 2007-08-29
HK1098386A1 (en) 2007-07-20
US7935690B2 (en) 2011-05-03
US20090124590A1 (en) 2009-05-14
MXPA04010311A (es) 2005-02-03
US7608606B2 (en) 2009-10-27
EP1425019A4 (en) 2004-11-17
US7608609B2 (en) 2009-10-27
CN1662243B (zh) 2011-10-26
US20160129016A1 (en) 2016-05-12
PL213976B1 (pl) 2013-05-31
ES2399900T3 (es) 2013-04-04
LT5235B (lt) 2005-06-27
US20090192132A1 (en) 2009-07-30
US7608605B2 (en) 2009-10-27
ATE371456T1 (de) 2007-09-15
IS2667B (is) 2010-08-15
MY139721A (en) 2009-10-30
US20080108590A1 (en) 2008-05-08
ZA200408422B (en) 2006-06-28
IS7535A (is) 2004-11-17
AU2003228612A1 (en) 2003-11-03
US20130281416A1 (en) 2013-10-24
TWI362932B (en) 2012-05-01
EP1741433A1 (en) 2007-01-10
KR100952786B1 (ko) 2010-04-14
LT2004101A (en) 2005-04-25
US20130059828A1 (en) 2013-03-07
US7320968B2 (en) 2008-01-22
CA2470200A1 (en) 2003-10-30
US7608610B2 (en) 2009-10-27
IL164547A0 (en) 2005-12-18
AR039644A1 (es) 2005-03-02
US20080275013A1 (en) 2008-11-06
US7608608B2 (en) 2009-10-27
US20080103120A1 (en) 2008-05-01
US20090192131A1 (en) 2009-07-30
US20100081640A1 (en) 2010-04-01
EP1741433B1 (en) 2012-11-07
KR100977896B1 (ko) 2010-08-24
HK1082682A1 (en) 2006-06-16
WO2003088974A1 (en) 2003-10-30
IS2946B (is) 2016-05-15
DE60315939D1 (de) 2007-10-11
PL372083A1 (en) 2005-07-11
US20090118250A1 (en) 2009-05-07
US8178518B2 (en) 2012-05-15
CY1109005T1 (el) 2014-07-02
US20080275012A1 (en) 2008-11-06
CN1662243A (zh) 2005-08-31
SA03240158B1 (ar) 2007-02-17
US20090118251A1 (en) 2009-05-07
EG24882A (en) 2010-12-01
TW200408397A (en) 2004-06-01
JP2005519985A (ja) 2005-07-07
US20150283153A1 (en) 2015-10-08
IL164547A (en) 2011-01-31

Similar Documents

Publication Publication Date Title
AR087484A2 (es) Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
HK1108703A1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
HUP0302468A2 (hu) Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
AR036213A1 (es) Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
AR098830A2 (es) Suspensiones acuosas estabilizadas para administración parenteral
ECSP088240A (es) Composición de trazodona para administración una vez por día
AR035885A1 (es) Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
BRPI0519345A2 (pt) composiÇço para tratamento do hcv
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
BR0013264A (pt) Compostos ou seus sais, uso dos mesmos, e, formulações farmacêuticas
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
AR071959A1 (es) Derivado de benceno o tiofeno y su uso como inhibidor de vap-1
PE20030727A1 (es) 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR081638A1 (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
UY27503A1 (es) Nuevos derivados de piperazina
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
CO5560555A2 (es) Cristales de derivado de hidroxinorefedrina
UY27980A1 (es) Indoles 2,7-sustituidos
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno

Legal Events

Date Code Title Description
FB Suspension of granting procedure